Lung Cancer

Top Story

Trial of lurbinectedin for small cell lung cancer meets primary endpoint

March 25, 2019
Meeting News

Toxicity, costs must be considered when using chemotherapy-immunotherapy combinations for lung cancer

March 25, 2019
Two faculty members at HemOnc Today New York debated whether immunotherapy alone or in combination with chemotherapy is the ideal treatment approach for lung…

Molecular therapy for lung cancer has not evolved quickly enough

March 22, 2019
Molecular therapy for the treatment of lung cancer has not evolved enough to adequately extend survival of patients, according to a presenter at HemOnc Today New York…
Meeting News

More immunotherapy regimens ‘desperately needed’ for salvage treatment of advanced NSCLC

March 21, 2019
NEW YORK — Results of the KEYNOTE-189 trial dramatically altered initial treatment for patients with advanced-stage non-small cell lung cancer whose tumors do not…
More Headlines »
CME CPE CNE

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Lung cancer is a leading cause of cancer death worldwide. The American Cancer Society estimates that there will be…
More »
Video
Meeting News

VIDEO: Targeted agents may fill unmet needs in non-small cell lung cancer

June 23, 2018
More »
Resource Centers
Discoveries from ASCO Lung Cancer

Discoveries from ASCO Lung Cancer

CME

Multimodality Treatment Strategies for NSCLC: A Symposium at the US Oncology Annual Meeting

This activity is supported by an educational grant from Merck & Co., Inc.

Lung cancer is a leading cause of cancer death worldwide. Approximately 85% of diagnosed lung cancers are non-small…
More »